Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770
Debt
Debt-to-Equity RatioN/A
Current Ratio4.14
Quick Ratio4.14
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-52.40
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-54,810,000.00
Net MarginsN/A
Return on Equity-870.35%
Return on Assets-92.92%
Miscellaneous
Employees20
Outstanding Shares57,610,000
Market Cap$150.94
Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
How were Bellerophon Therapeutics' earnings last quarter?
Bellerophon Therapeutics Inc (NASDAQ:BLPH) announced its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. View Bellerophon Therapeutics' Earnings History.
When is Bellerophon Therapeutics' next earnings date?
What price target have analysts set for BLPH?
1 equities research analysts have issued 12-month target prices for Bellerophon Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Bellerophon Therapeutics' share price to reach $5.00 in the next year. This suggests a possible upside of 90.8% from the stock's current price. View Analyst Ratings for Bellerophon Therapeutics.
What is the consensus analysts' recommendation for Bellerophon Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Bellerophon Therapeutics' key competitors?
Some companies that are related to Bellerophon Therapeutics include Five Prime Therapeutics (FPRX), Beyondspring (BYSI), Geron (GERN), Prothena (PRTA), Akebia Therapeutics (AKBA), Insys Therapeutics (INSY), Aduro BioTech (ADRO), CannTrust (CNTTF), Merus (MRUS), Keryx Biopharmaceuticals (KERX), Depomed (DEPO), Magenta Therapeutics (MGTA), ArQule (ARQL), Arcus Biosciences (RCUS) and Rigel Pharmaceuticals (RIGL).
Who are Bellerophon Therapeutics' key executives?
Bellerophon Therapeutics' management team includes the folowing people:
- Mr. Fabian Tenenbaum, CEO & Director (Age 44)
- Dr. Deborah A. Quinn, Chief Medical Officer (Age 64)
- Mr. Peter Fernandes, Chief Regulatory & Safety Officer (Age 63)
- Mr. Assaf Korner, CFO & Sec. (Age 40)
- Ms. Amy Edmonds, VP of Clinical Operations & Admin. (Age 46)
When did Bellerophon Therapeutics IPO?
(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
Has Bellerophon Therapeutics been receiving favorable news coverage?
Media headlines about BLPH stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bellerophon Therapeutics earned a daily sentiment score of 0.24 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Bellerophon Therapeutics?
Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellerophon Therapeutics' stock price today?
One share of BLPH stock can currently be purchased for approximately $2.62.
How big of a company is Bellerophon Therapeutics?
Bellerophon Therapeutics has a market capitalization of $150.94 million. The biotechnology company earns $-54,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Bellerophon Therapeutics employs 20 workers across the globe.
How can I contact Bellerophon Therapeutics?
Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]
MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
